← Leaderboards
Hartmut Geiger
Children'S Hospital Med Ctr (Cincinnati)
$4,537,856
Attributed
$7,493,656
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2005–19$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$7,493,656 · 11
By mechanism
R01$4,459,793 · 3
R43$2,231,363 · 6
R21$412,500 · 1
R56$390,000 · 1
Top collaborators
- Yi Zheng15 shared
- Jose A. Cancelas1 shared
- Ying Liang1 shared
- James C Mulloy1 shared
Most similar at Children'S Hospital Med Ctr (Cincinnati)
Same institution · by research overlap
- Timothy P Cripe$10,144,846
Others in their field
Top investigators on “Hematopoietic Stem Cells”
- Mary M Horowitz · Medical College Of Wisconsin$222,127,419
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$80,540,126
- David T Scadden · Massachusetts General Hospital$40,987,034
- David A Williams · Indiana Univ-Purdue Univ At Indianapolis$36,503,708
- Irving Lerner Weissman · Stanford University$36,281,548
- Bruce R. Blazar · University Of Minnesota$33,175,355
Research focus
Hematopoietic Stem CellsHematopoieticStem CellsCellsTissuesMolecularAffectBloodBone MarrowCell AgingPlayCell AgeHomeostasisAgedTransplantationFutureBlood CellsCell LineagePhenotypeAnimalsInhibitor/AntagonistLongevityLymphoidPublishing
Grant awards (24)
Blood stem cell aging and biomarker studies$390,000
R01 · FY2019 · HL
Targeting Latexin for radiation mitigation.$297,014
R43 · FY2019 · AI · contact PI
Blood stem cell aging and biomarker studies$390,000
R01 · FY2018 · HL
Activated protein C peptides for radio-mitigation$292,594
R43 · FY2018 · AI · contact PI
Blood stem cell aging and biomarker studies$390,000
R01 · FY2017 · HL
Activated protein C peptides for radio-mitigation$298,750
R43 · FY2017 · AI · contact PI
Blood stem cell aging and biomarker studies$390,000
R01 · FY2016 · HL
Stem cell aging and biomarker studies$390,000
R56 · FY2015 · AG
Lineage Determination and Tissue HomeOstasis in the aged Hematopoietic System$333,922
R01 · FY2015 · AG
A non-myeloablative conditioning regimen for hematopoietic stem cell transplantat$366,718
R43 · FY2014 · HL · contact PI
Lineage Determination and Tissue HomeOstasis in the aged Hematopoietic System$344,250
R01 · FY2014 · AG
Targeting the Core Binding Factor tumor suppressor in MLL-fusion AML$224,629
R43 · FY2014 · CA · contact PI
Lineage Determination and Tissue HomeOstasis in the aged Hematopoietic System$325,316
R01 · FY2013 · AG
Improving hematopoietic stem cell mobilization by the EGFR inhibitor Erlotinib$390,255
R43 · FY2012 · HL · contact PI
Pharmacological rejuvenation of aged hematopoietic stem cells.$361,403
R43 · FY2012 · AG · contact PI
Lineage Determination and Tissue HomeOstasis in the aged Hematopoietic System$344,250
R01 · FY2012 · AG
Lineage Determination and Tissue HomeOstasis in the aged Hematopoietic System$38,250
R01 · FY2012 · AG
Lineage Determination and Tissue HomeOstasis in the aged Hematopoietic System$344,250
R01 · FY2011 · AG
Young Stem Cell Potential in Aged Mice$225,000
R21 · FY2009 · DK · contact PI
Young Stem Cell Potential in Aged Mice$187,500
R21 · FY2008 · DK · contact PI
Genetic Reg. of Hematopoietic Stem Cell Mobilization$282,558
R01 · FY2007 · HL · contact PI
Genetic Reg. of Hematopoietic Stem Cell Mobilization$290,997
R01 · FY2006 · HL · contact PI
Genetic Reg. of Hematopoietic Stem Cell Mobilization$298,000
R01 · FY2005 · HL
Genetic Reg. of Hematopoietic Stem Cell Mobilization$298,000
R01 · FY2004 · HL